Company News & Publications

Breaking News

DUBLIN, IRELAND, August 2, 2012
Druggability Technologies Appoints Louis Scotti as Chief Business Development Officer

Druggability Technologies Holdings Limited (DRGT) today announced the appointment of Louis Scotti to the newly created position of Chief Business Development Officer. Mr. Scotti will be responsible for all business development activities and managing the company’s numerous existing collaborations for its NanoActive^TM technology platform.

Upcoming events

22-25 April 2013, Chicago, USA
BIO International Convention

30 April-1 May 2013, San Diego, USA
3^rd DDF Americas Summit

Latest events

11-13 March 2013, Barcelona, Spain
Bio-Europe Spring 2013

18 - 20 February 2013, Berlin, Germany
4^th Annual DDF Summit

21 - 23 January 2013, Boston, MA, USA
2^nd Enhancing Drug Solubility and Bioavailabilty

7 - 9 January 2013, San Francisco, CA, USA
Biotech Showcase

28 - 30 November 2012, Boston, MA, USA
Therapeutic Area Phartnerships

12 - 14 November 2012, Hamburg, Germany
BioEurope 2012

14 - 17 October 2012, Toronto, ON, Canada
LES Annual Meeting 2012

7-9 October 2012, Brussels, Belgium
BioPartnering Future Europe

Latest Press Release

SAN FRANCISCO, CA, January 12, 2012
Druggability Technologies Announces Financial Investment by SPCH

Druggability Technologies Holdings Limited (DRGT), a privately held biotechnology platform company, announced today that it has completed an initial round of financing totaling $4,000,000.

Budapest, Hungary, 11 Janurary 2011
NanGenex successfully validated its latest GMP compliant industrial scale NanoPilot™ instrument

Nangenex Inc. has successfully completed the chemical validation of its lates GMP compliant pilot plant reactor. This is the first milestone towards fulfillin production needs of the clinical development of NanGenex's NanoActive™ products.

Budapest, Hungary, 31 August 2010
NanGenex to introduce the new GMP compliant industrial scale NanoPilot™ instrument

Nangenex Inc., the Proprietary NanoSolution Technology Platform Company presents its latest GMP compliant benchtop and pilot pant reactor for the industrial scale production of NanoActive™ nanoparticles.

Read this article

See the intsruments

Budapest, Hungary, 27 July 2010
In vivo data confirms effectiveness of the NanoActive™ technology in imrpoving bioavailability

Budapest, Hungary - Nangenex Inc., the proprietary NanoActive™ continuous flow technology platform company has completed the first round in vivo testing of NanoActive™ nanoformulations of blockbuster drugs.

Budapest, Hungary, 13 April 2010
NanoForm Cardiovascular Therapeutics Ltd, London, UK established for the further development and commercialization of proprietary NanoActive™ formulations of two blockbuster drugs for cardiovascular indications.

Budapest, Hungary, 12 October 2009
ThalesNano signs strategic alliance with NanGenex to offer revolutionary nanosizing continuous flow technology service.

Budapest, Hungary, 03 September 2009
Proprietary continuous flow NanoActive™ technology to formulate nanosized active molecules from NanGenex.

Papers

MST News, 2008, 3(8), 30-31
Niesz, K.; Wootsch, A.; Otvos, Zs.; Darvas, F.
Synthesis of Nanostructures on a Microfluidic-based Flow Device

Microfluidics and Nanofluidics, 2008, 1613-4982
Niesz, K., Hornyak, I., Borcsek, B., Darvas, F.
Nanoparticle synthesis completed with in situ catalyst preparation performed on a high-pressure high-temperature continuous flow reactor